• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU1440348A3
    申请号:SU853995762
    申请日:1985-12-13
    公开日:1988-11-23
    发明作者:Мертенс Альфред；Хельк Иенс-Петер；Кампе Бернд Мюллер-Бекманн Вольфганг；Штрайн Клаус；Шауманн Вольфганг
    申请人:Берингер Маннхайм Гмбх (Фирма)；
    IPC主号:
    专利说明:

    (21) 3995762 / 23-04
    (22) 12/13/85
    (31) P 34456694
    (32) 12/14/84
    (33) DE
    (46) 11/23/88. Bul No. 43
    (71) Beringer Mannheim GmbH (DE)
    (72) Alfred Marten, Jens-Peter Helk, Wolfgang Kampe Bernd Müller-Beckmann, Klaus Strein and Wolfgang Schaumann (DE)
    (53) 547.781.785.07 (088.8)
    (56) Elderfield R. Heterocyclic Compounds. V. 5, 1954, p. 221-223.
    (54) METHOD FOR OBTAINING PYRROLO-BENZYMIDAZOLES OR THEIR PHYSIOLOGICALLY COMBINABLE SALTS OF INORGANIC ACIDS
    (57) The invention relates to heterocyclic compounds, in particular to the preparation of pyrrolo-benzimidazoles of the formula
    RI RZ i
    hc ooN N NN
    where lower alkyl or cycloalkyl, R2 lower alkyl, cyano or lower alkoxycarbonyl or together with R forms lower cycloalkylene, RJ, R and RJ may be the same or different and each H atom, alkoxy group, lower alkyl, halogen atom, alkylsulphonyloxy group, amino-acetylamino group, 1H-imidazole, alkylsulphonylamino, cyanocarbonyl, aminocarbonyl, alkoxycarbonyl, apkilmercapto, dialkylamino, trifluoromethyl, alkylsulphinyl or alkylsulphonyl, ace, chlorofluoromethyl, trifluoromethyl, alkylsulphinyl or alkylsulphonyl, acelmercapto logically compatible salts of inorganic ki slot having biological activity. The chain is the development of a method for obtaining new more active compounds. Synthesis is carried out from a compound of the formula (NH) -C (III) CH-CH-CH-N (H) -C (0) -CR, R 2 and Y-C (0) -C6HiR3R4Rf, where RI, R; and Rj, R4R j is indicated above, and Y is H or halo. The desired product is in free form or as a salt with an inorganic acid. 5 tab.
    I
    WITH
    four
    four;
    about
    00 4
    00

    O1
    This invention relates to novel pyroprobenzimidazoles possessing biological activity.
    The purpose of the invention is the synthesis of new compounds that are superior in their activity to known compounds possessing the same activity.
    An example. 7-Yzopropyl-2- (4-methoxy-phenyl) -6,7-dihydro-3N, 5H-pyr rolo (2,3-f) benzimidazole-6-OH. 2.8 g (13.6 mmol) of 5,6-diamino-3-isopropyl indolin-2-OH-dihydrochloride were suspended in 10 MP, mixed with 2.55 g (15 mmol) of P-methox-
    benzoyl chloride, and at 25 ° C, 4.55 g (45 mmol) of triethylamine was added as drops. Then the mixture was stirred for 2 hours, concentrated and treated with water. The residue was heated for 24 hours to obtain reflux, concentrated and neutralized with 2N ammonia. The octane residue was recrystallized from ethyl acetate; methanol. Yield 2.1 g (48.2%), t, mp 326-328 ° C.
    Analogously to Example 1, compounds are obtained which are given in
     tab. one.
      ,Table
    one




    45
    328-30
    Ethanol /
    water
    23
    300-03 Acetone
    - - o - 15
    20 /; 25
    thirty
    Continuation
     11E1
    eleven
    29
    2-methoxybenzoyl chloride
    7,7-Dimethyl-2- (4-46
    toxy-phenyl) -6,7 dihydro-3H, 5H-pyrrolo (2,3-) benzimidazole-6-OH
    of
    5,6-diamino-3,3dimethyl-indolin2-OH
    7,7-Dimethyl-2- (4 chlorophenyl) -dihydro-3H, 5H-pyrrolo
    (2,3-f) benzimidazal-6-OH
    of
    5,6-diamino-3, 3-dimethyl-indolin-2-OH and
    4-chl or b e n 3 oyl chlide 7,7-dimethyl-2- (2-methoxy-5-methylsulfonyl-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2 , 3-f) benzimide-ZOL-6-OH from
    5,6-diamino-3,3-dimethyl-indoline-2-OH
    table 1
    3
    341-43
    Dioxane /
    water
    2: 1 360-63
    236-38
    Ethanol /
    water
    five
    0
    five
    0
    five
    2-methoxy-5-methyl-sulfonyl-benzoyl chloride
    7,7-Di1 eth1-2- (4-methyl-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) midazol-6-OH from
    5,6-diamino-3,3-dimethyl-indblin-2-OH and
    4-methylbenzoyl chloride
    7,7-Diethyl-2- (4-methoxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) beisimidazole-6-OH from
    5,6-diamino-3, 3-d and e-and-nd ol and n - 2-OH
    thirty
    /(four
    300
    Isopropanol
    217-19
    Ethyl
    ether
    acetic acid
    354-55 Dioxane / water 1: 1
    ten
    15
    300
    Acetic ether / methanol
    Prod, must table. one
      TG
    and
    4-methoxybenzoyl chloride
    2- (4-Methoxy-fe-37
    nyl) -spiro cyclopentane-1, 7-6, 7-dihydro 3 N., 5H-pyrrolo (2; 3-f) l benzimidazole-6-OI from
    5,6-diamino-spiro (cyclopentan-1,3-indoline) -2 -OH and
    4-methoxybenzoyl chloride
    7-Methyl-2- (4-metho-43 xy-phenyl) -6,7di-hydro-ZN, 5H-pyrrolo (2,3-f) benzimidazol-6-OH from
    5,6-diamino-3-methyl-indolio-2-OH-dihydro-chloride and
    7-Methyl-2- (2,4-12 dimethoxy-phenyl) -6,7-dihydro-3H 4-methoxybenzoyl chloride, 6H-pyrrolo (2,3-) benzimidazole-6 -He is from
    5,6-diamino-3-methyl-indo-LIN-2-OH di-hydrochloride and
    2,4-dimethoxy-45
    benzoyl chloride
    1 / D / 40348
    5.4 g (014 mol) of this compound are hydrogenated in 200 ml of methanol in the presence of 0.5 g of 10% palladium g on carbon at normal pressure. The catalyst is sucked off and the solvent thickens in vacuo. 1.8 g (44%) of the title compound are obtained in the form of colorless crystals with m.p. 240 ° C (acetone).
    II p and me R 3. 7-Methyl-2- (2-methoxy-4-amino-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH- hydrochloride. 3.5 g (14 mmol) of 5,6-diamino-3-methyl-indolin-2-OH-dihydrochloride, 4.5 g (21 mmol) of 2-methoxy-4-nitro-benzoyl chloride and 6.95 ml (49 mmol) of triethylamine is stirred in 50 ml for 3 hours at room temperature. Then distillation is carried out for the purpose of drying, treatment with water and recrystallization from methanol-methylene chloride. 3 g of a mixture of mono and diamide are obtained.
    2.6 g of the product thus obtained is hydrogenated in 400 ml of methanol with 0.8 g of 10% palladium / carbon. After the water absorption is complete, the catalyst is sucked off, the methanol is separated by distillation, and the residue with 70 MP of ethanol and 35 ml of concentrated hydrochloric acid is subjected
    ether / methanol 35 boiling for 24 hours. The solvent is separated by distillation and the oily residue crystallizes from ethanol. Obtain 1.1, g of compound with m, pl. 280-310 S.
    Analogously to Example 3, compounds are obtained which are listed in Table. 2. T a b e c i a 2
    20
    25
    thirty
    294-97 Acetic
    40
    And pmmere 2. 7,7-Dimethyl-2- (4-hydroxy-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-) benzimidazole-6-OH. A solution of 3.6 g (0.019 mol) of 5,6-diamino-3,3-dimethyloxindole and 4.0 g (0.019 mol) of 4-benzyloxybenzaldehyde is heated to boiling in 100 ml of ethanol by passing air. After 1 h, cooling is carried out and the precipitated precipitate is removed. 5.4 g (74%) of colorless crystals are obtained.
    with t. pl. 250 C.
    ten
    g
    15
    20
    25
    thirty
    40
    7,7-Dimethyl-2- (2- 18,295 methoxy-4-amino-fe-ethanol
    Nile) -6,7-dihydro-3H, 5H, pyrrole o (2,3-f) benzimidazole-6-OH hydrochloride
    7-Ethyl-2- (2-labels-10 274 si-4-amino-phenyl) -ethanol
    6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH-hydroxinopjjfl
    EXAMPLE 4 7-Ethyl-2- (2-methoxy-4-acetylaminophenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-) benzimidazol-6-OH .
    0.7 g (1.8 mmol) 7-ethyl-2- (2-m-x-4-amino-phenyl) -6,7-dihydro-3H, 5H-PIRROLO (2,3-f) benzimidazole-6- OH-hydrochloride, 15 ml of acid tetanhydride and 0.3 g of sodium acetate are stirred for 3 hours at 40 ° C. After cooling, suction is performed, after crystallization with carbon, crystallization occurs. Yield 0.44 g (69%) 5 tons pl. 245-249 ° C.
    Example 5. 5.7,7-Dimethyl-2- / L4- (1H-imidazol-1-Sh1) -phenyl} -6,7-dihydrr-3N, 5H-pyrrolo (2,3- f) benzimidiol-6-OH, 2.0 (10.4 mmol), 5,6-diamino-3,3-dimesh-1-indolin-2-OH, 2.8 g (10.4 mmol) 4- ( 1H-imidazol-1-yl) -benzaldehyde, 0.2 g (2 mmol)
    R-TOLUOLSULPHONIC acid and 120 MJ
    the ethanol is stirred and air is passed through for 3 hours after reaching the boiling point.
    After concentration and acidification with ethanol and hydrochloric acid, the crystals are sucked off, suspended in water and neutralized with aqueous ammonia. The residue is recrystallized from methanol. The output of 1.0 g (28%), so pl, 300 C.
    Analogously to example 5, receive the connection, which is given in table. 3 Table 3
     ) -
    H
    eh
    23
    272-70
    Isopropanol
    EXAMPLE 6: 7,7-Dimethyl-2- (2-methoxy-4-methylsulfonylaminophenyl) 6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH . In a solution of 3.6 g (10 mmol) of 7,7-dimethyl-2- (2-methoxy-4-amino-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole- 6-OH hydrochloride and 2.2 g (22 mmol) of triethylamine in 50 ml of dimethylformamide are slowly added as drops of 1.26 g (11 mmol) of methanesulfonyl chloride. 0 After stirring for 2 hours at 25 ° C, dimethylformamide is distilled off under high vacuum, the residue is treated with water and sucked off. This is then recrystallized from ethanol. The yield of 2.9 g (72.5%), so pl. 300 ° C.
    EXAMPLE 7 7,7-Dimethyl-2- (2-methoxy-4-cyan-phenyl) -6,7-dihydro-3H, 5H-pyrrilo (2,3-f) benzimidazol-6- o HE. To 17.7 g of 4-cyano-2-methoxy-benzoic acid (mp. 170-173 0) in 180 ml of dichloromethane, while cooling, 22.9 g (0.11 mmol) of PC150 are added in portions
    5 The solvent was removed in vacuo and the residue (acid chloride) was used without further purification.
    9.8 g (0.05 mmol) of this residue are taken up in 50 ml of dichloromethane, 0 are charged with 6.9 ml (0.05 mmol) of triethylamine and 5.7; D (0.03 mmol) of 5.6 diamino -3,3-dimethyloxindole and stirred at room temperature. After filtration, the solvent is removed under vacuum and the residue is used without further purification.
    5.3 g of the residue is heated in 200 ml of ethanol and 30 ml of concentrated hydrochloric acid for 3 hours to obtain reflux. The solvent is removed under vacuum, and the residue is taken up with ammonia solution. After chromatographic purification (kiesel gel, dichloromethane: methanol — ammonia r. 20: 1, and toluene: ethyl acetate: acetic acid 5: 5: 1), 1.4 g of the title compound are obtained in the form of an acetate with m.p. 304-312 ° C.
    EXAMPLE 7.7-Dimethyl-2- (2-methoxy-4-carboxy-phenyl) -6,7-dihydro-3N, 5H-pyrrole o (2, 3-f) benzimide-ZOL -6-OH. 0.4 g (1.2 mmol) of 3,3-dimethyl-2- (2-methoxy-4-cyan-phenyl) -5.6.7-dihydro-3N, 5H-pyrrolol (2.3-f ) The benzimidazole-6-OH is heated with 4 ml of 2N sodium oil for 1 hour to obtain phlegm. Then cooling is carried out, acidification is carried out.
    five
    0
    71A
    glacial acetic acid and crystallization are sucked off,.
    Output 0.4 g (95%), so pl. 315i319 ° C.
    II p-meper 9, 7,7-Dimetsh1-2- (2-methox-4-aminocarbonyl-phenyl) -6,7-dihydro-3N, 5H-pyrroles (2,3-f) benzimidazole- -6-OH. 0.25 g (0.71 mmol) of 7,7-dimethyl-2- (2-methoxy-4-carboxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole 6-OH is heated with 2 MP of thionyl chloride at boiling point for 3 hours to obtain reflux and then evaporated to dry. The acid chloride is suspended in 2 ml of dioxane and added dropwise in 2 ml of concentrated A1 "miak. Then stirring is carried out for 1 hour at 80 ° C, stripping of dioxane and water, stirring the residue with water and sucking. The output of 0.15 g (60%), so pl. 265-270 seconds
    Example 10. 7,7-Dimethyl-2- (2-methoxy-4-ztoxycarbonyl-phenyl) -6X7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH. 0.25 g (0.71 mmol) of 7,7-dimethyl-2- (2-methoxy-4-carboxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole 6-OH is heated with 2 MP of thionyl chloride for 3 hours at boiling point to obtain reflux and then evaporated to dry. The acid chloride is mixed with 5 MP of ethanol and boiled for 1 hour to obtain reflux, after which it is cooled and hydrophthalisate sucked off.
    The output of 0.16 g (59%), so pl. 235-,
    Example 11. 7,7-dimethyl-2- (2-methoxy-4-hydroxy-phenyl) -6,7-di
    eight
    hydro-ZN, 5H-pyrrolo (2,3-f) benzimide-ZOL-6-OH, Analogously to Example 1 from 2.0 g (10.4 mmol) of 5,6-diamino-3,3-dimethyl-indoline 2-OH and 5.75 g- (20.8 mmol) of 4-benzyloxy-2-methoxy-benzoyl chloride give the title compound. Output 2.1 g (62.5%), so pl. 225-240 ° C.
    Example 12., 7,7-Dimethyl-2 (2-methoxy-4-methyl-methylphenyl-phenyl) -6, 7-dihydro-3H, 5H-Pyrrolo (2, benzimndazol-6-OH. In a solution of 1.5 g (4.6 mmol) 7,7-dimethyl-2- (2-methoxy-4-hydroxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-OH and 0 , 46 g (4.6 mmol) of triethylamine c 20 ml of dimethylformamide are added in the form of drops at 0.53 g
    (6 mmol) methanesulfonylsloride. After 2 hours, dimethylformamide is distilled off under vacuum. The residue is treated with water and sucked off. The residue is recrystallized from ethanol. Vkod
    1.3 g (70.6%), so pl. 233-235 ° C.
    Example 13: 7,7-Dimethyl-2- (2-methoxy-4-methyl-methylphenyl-phenyl) - 6,7-dihydro-3H, 5H-pyroprol (2,3-f) benzimidazole-6-OH. 200 mg (0.56 mmol)
    7,7-dimethyl-2- (2-methoxy-4-methyl-M8rcapto-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimidazol-6-OH for 48 h at room temperature is stirred in 4 ml of glacial acetic acid
    acids and 0.4 ml of 30%, j. 10 ml of water are added and the solvent is removed under vacuum. 160 mg of the title compound are obtained after crystallization from ethanol with m, mp. 235237 ° C.
    In tab. 4 shows the elemental analysis data.
    Table 4,
    Example
     internal cue f 2705
    1st
    X 2 N, 0
    If - X COj to 1g2
    th1i X CO 1j X 0.5
    2X 0.75 acetone
    3X 0.75 Over
     0,2 HjO
    3s
    four
    4a 4b 5 6
    6a 7 8 9 10
    1 12
    3 14
    54.15 64.57 71.62 72.05 64.09- 65.04 65.95 70.21 67.64 66.92. 63.25 56.28. 57.37 57.37
    X COji X 1.25 HjO 58.53 X 1.25, 65
    X CO X 1.25 HjO 57.93 64.57 57.00 65.04 64.95
    65.13 66.48
    66.86 65.38
    X
    X
    X
    X 0.75 CHjCOOH
    53.90
    64.55
    70,88
    71,83
    63.93
    65.03
    66.25
    69,8
    67.11
    66.33
    63.25
    56,43
    57,12
    57.80
    57,84
    65.74
    57.52
    64.05
    56,82
    64.99
    64.54
    X 0.5 CiHyOH X
    X 0.5 HiO
    59.21
    5.30
    5.68
    6.33
    5.63
    4.66
    5.31
    6.65
    5.32
    5.68
    5.53
    4.74
    5.30
    5.49
    5.48
    5.29
    5.04
    5.63
    5.38
    5.05
    5.15
    4.53
    9.97 11.89

    12.53 12.60 12.46 12.64 12.47 14.44 12.45 12.32 12.29 14.44 14.87 14.87 13.00 19.14 12.87 11.89 13, 99 14.73 11.96
    9.89 7.6 12.34 12.09 12.59 13.08 12.46 12.06 13.86 11.97
    11.85 Chlorine 12.02 10.4 15.28 9.7 14.92 9.4 14.73 9.4 13.00 13.30 19.08
    13.18 8.1 11.59 9.1 13.75 8.0 14.11 11.50
    7.5
    9.9
    9.6
     Chlorine 9.2 Chlorine 9.3
    Chlorine 8.1 Sulfur 9.1 Sulfur 8.0
      I
    Analogously to Example 1, the following compounds are also prepared.
    7-Ethoxycarbonyl-7-methyl-2-feii. 11 6, T-dihydr o-3H, 3N-pyrrolo- (2,3-f) benzimidazole-b-OH (t used as starting compounds 5,6-dia - mino-3-ethoxycarbonyl-3-methyl-indolin-2 OH and benchoyl chloride). You hst 29%, so pl. 178-182 C.
    7,7-Dimethyl-2- (4-trifluoromethyl phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH (5,6-, diamino -3,3-dimethyl-indilin-2-OH and 4-trifluoromethylbenzoyl chloride). Yield 48%, so pl. 300 ° C.
    7,7-Dimethyl-2- (2-methoxy-4-me- {methylsulfinyl-phenyl) -6,7-dihydro-ZI, pH-pyrrolo (2,3-f) benzimidazole-6-OH (used as starting compounds 5,6-diamino-3, 3-dimethyl-indoline-2-OH-2-methoxy-4-metsyl sulfonyl-benzoyl chloride). Yield 21%, t, pl. 21.
    7,7-Dimethyl-2- (phenyl-vinyl) -6,7-dihydro-3N, 5H-pyrrole- (2,3-f) benzimidazole-b-OH (used as starting compounds 5,6-diamino- 3,3-dimethyl-indolin-2-OH and cinnamoyl chloride). Yield 34%, so pl. 320-325 ° C.
    The proposed compounds are usually used in amounts from 10-500 mg per day in relation to 75 kg body weight. Preferably, 1-2 tablets with a biologically active substance of about 5-200 mg should be given 2-3 times a day.
    Tablets can be taken less often, so you should take only 1 time per day for 1-2 tablets with 10-500 mg of biologically active substances.
    The biologically active substance can also be taken by injection 1-8 times per day or by long-term infusion, and quantities of 5-200 mg / day are sufficient,
    In addition to the compounds given in the examples, their tautomers were also tested.
    7,7-dimethyl-2- (4-nitrophenyl) -6,7-dihydro-ZP, 5H-pyrrolo (2,3-) benzimidazole-6-OH;
    7,7-dimethyl-2- (4-amino-phenyl) -6,7-dihydro-3H, 5H-PIRROLO (2,3-f) benzimidazole-b-OH;
    81-7, 7 - lima-1 yl-2- (2-yr1lroksi. And fennp) - 6. 7-digpdr () - 311, 5P-pyrrolo (2,3-f) benzimidazole - 6 -HE;
    1,7-dimethyl- (2-dlmetipamino-2-nitro-phenyl) -6,7-dihydro-3H, 5H-pyr-po.iio (2,3-f) benzimilazole-6-OH:
    7,7-dimethyl-2- (3,4-dichloro-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-b-OH;
    7,7-dimethyl-2- (phenyl-vinsh1) -6,7-dihydro-3N, 5H-pyrrolo (2,3-) benzimidyazole-6-OH, t. Pl. 320-325 C;
    7,7-dimethyl-2- (3,4-dimethoxy-phenyl-vinyl (-6, 7-dihydro-3H, 5H-pyrrapo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-amino-carbonylamino-phenyl) -6,7-dihydrr-3H, 5H-pyrrolo (2,3-) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-methyl minocarbonylaminophenyl) -6,7-dihydro 3N, 5H-pyrrolo (2,3-f) benzimidazole-6-O
    7,7-dimethyl-2- (2-methoxy-4-trift-ormethylsulfonyloxy-phenyl) 6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-methyl-sulfonyloxy-phenyl) -6,7-dihydro-3H, 5H-pyrrole o (2,3-f) benzimidazol-6-OH;
    7, 7-dimethyl-3- {2-methoxy-4-amino-sulfonyl-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-di-methyl-aminocyl-phenyl-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-b-OH;
    7,7-dimethyl-2- (2-methoxn-4-p-ethyl aminosuconophyl-phenyl) -6,7-dihydro-3H, 5H-pyrrole o (2,3-f) benzimidazole-6-OH;
    7,7-di methyl-2- (2-methoxy-4-4-morpholinyl-sulfonyl-phenyl) -6,7-dihydro-3H, 5H-PIRR olo (2,3-f) benzimidazole-b-OH;
    7,7-dimethyl-2- (2-methoxy-4-methyl sulfenylmethyl-phenyl) -6,7-dihydro-3H, 5H-pyrrol o (2,3-f) b en-zimidazol-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-methyl sulfinylmethyl-phenyl) -6,7-dihydro-3H, 5H-pyrrole o (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-nitro-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimcdazol-6-OH;
    7,7-dimethyl-2- (2-methoxy-4H-methylsulfonylaminophenyl) -6,7-dihydro10
    131440348
    3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-methylsulfonyl-phenyl) -6,7-dihydro-ZN.N.-pyrrolo (2, 3-f) benzimidazole-6-OH5, so pl. 217-220 ° C.
    7,7-dimethyl-2- (4-trifluoromethyl-phenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OH, t. Pl.
    7,7-dimethyl-2- (2-methoxy-4-methylsulfonylmethyl-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-methyl-aminocylphenyl-phenyl) -6, 7-dihydg) o-3H, 3H-pyrpole (2,3-f) benzimidazol-6-OH;
    7, 7-dimethyl-2- (2-methoxy-4-gg1: 10-pargyloxy-phenyl) -6,7-dihydro-ZN, ZN-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-dimethyl-2- (2-methoxy-4-1 schanme tyloxy-fensh b, 7-dihydro-3N 5H-pyrpro (2,3-f) -bie1nzimidazole-6-OH;
    7,7-dimethyl-2- (2-labels, si-4-methoxycarbonylmethyloxy-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-) benzimI3dazol-6-OH;
    7,7-dimethyl-2- (3,4,3-trimethoxyenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-diztil-2-phenyl-6,7-dihydro-ZN, 3N-pyrrolo (2,3-f) benzomidazole-6-OH;
    7,7-diethyl-2-p4- (1H-imidazol-2-yl) -enyl} - 6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazol-6-OH;
    7, 7-di-ethyl-2- (2,4-dimethoxy-f e-nyl) -6, 7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-diethyl-2- (2-methoxy-4-hydroxy-phenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) beisimidazol-6-OH;
    25
    5 f
    mi
     f
    20 W
    with s
    p h
     with
    35 p
     f p
    n p 5
    thirty
    7,7-diztil-2- (2-methoxy-4-methyl-sulfonyloxy-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidaz ol-6-OH;
    7-methyl-2- (2-methoxy-4-ethyl-sulfonyl-phenyl) -6, 7-dihydro-3, 3N-pyrrolo (2 5 3-f) benzimidazole-6-OH; 57-methyl-2- (2-methoxy-4-trifluoromethylsulfonyloxy-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (4-dimesh1amino-phenyl) / - MKiruii. h.h / j fimc: i lajidrojnnvj i jcnnji /
    7,7-diethyl-2- (2-methoxy-4-trifluoro-50 6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benmethylsulphonyloxy-phenyl) -6,7-dihydro-3N, 3N -pyrrolo (2,3-f) benzimidazole-6-0 ";
    7,7-diethyl-2- (2-methoxy-4 methylsulfonamide-phenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidaz ol-6-OH;
    7, 7-diethyl-2- (2-methoxy-4-metsh1-sulfenylmetsh1-phenyl) .- 6, 7-dihydro-.
    aimidazole-6-OH;
    7-methyl-2- (2-dimeshiamino-4-nitro-phenyl) -6 5 7-dihydro-3H, 3H-pyrrolo gg (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-nitrophenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-hydroxy0
    25
    3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7,7-diethyl-2- (2-methoxy-4-cyano-5 phenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OH;
    2-phenyl-spiro 1y clopentan-1,7 - 6,7 -dihydro-3 H, 3 H-pyrrolo (2,3-f) J benzimidazole-6-OH;
    2- (2-methoxy-4-methylsulfonylamino-phenyl) -spiro (hclclopentane-, 7-6-7-dihydro-3 H, 3 H-pyrrolo (2,3-f) 1-benzimidazol-6-OH;
    2 - (2-methoxy-4-trifluoromethylsulphonyloxy-phenyl) -spiro Cyclopentane-1, 7 -6, 7 -dihydro-3 H, 3 H-pyrrolo (2, 3-f) benzimidazol-6-OH;
    (2-methoxy-4-nitrophenyl) -spiro 11 1 -clopentan-1, 7 -6, 7-dihydro-20 Z H, 3 H-pyrrolo (2, 3-f) benzimidazol-6 -OH;
    2 (2-methoxy-4-hydroxy-phenyl) -spiro-cyclopentane-1,7-6.7-dihydro-3 N, 3 H-pyrrolo (2, 3-f) benzimidazole-6 -OH;
    (2-methoxy-4-amino-phenyl) -spiro-clopentan-1,7 -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-b -OH;
    2- (2-methoxy-4-methylsulfonyloxy-phenyl) -spiro-cy1; Scopentane-1,7- 6,7 -dihydro-3H, 3H-pyrrolo (2,3-f) J benzimidazol-6 -OH;
    7 methyl-2-phenyl-6, 7-dihydro.ro-3N, 3N- 35 pyrrolo (2,3-f) benzimidaz6l-6-OH;
    7-methyl-2 4- (1H-imidazol-1-yl) phenyl-6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OI;
    7-methyl-2- (2-methoxy-4-methylsulfonylamino-phenyl) -6.7 dihydro-3N, 3N-pyrupole (253-f) benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-ethyl-sulfonyl-phenyl) -6, 7-dihydro-3, 3N-pyrrolo (2 5 3-f) benzimidazole-6-OH; 57-methyl-2- (2-methoxy-4-trifluoromethylsulfonyloxy-phenyl) -6,7-dihydro-3N, 3N-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (4-dimesh1amino-phenyl) 30
    / - mkiruii. h.h / j fimc: i lajidrojnnvj i jcnnji /
    50 6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benaimidazole-6-OH;
    7-methyl-2- (2-dimeshiamino-4-nitrophenyl) -6 5 7-dihydro-3N, 3H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-nitrophenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-hydroxyphenyl) -6, 7-dig1ifo-311, 3N-pnrrop (2,3-f) benzimidazole 6-OH;
    7-methyl-2- (2-methox 1-4-ami11ocar-bonnlamino-phenyl) -6,7-digdro-3N, iH-pyrrolo (2,3-) benzimide-6-OH;
    7-methyl-2- (2-met. Zhsn-4 cyan-phenyl) -6,7-ЗН, 5H-pyrrolo (2,3-f) benzimidazol-6-OH;
    7-methyl-2- (2-methoxy-4-methylsulfonyloxy-fenchO-b, 7-dihydro-3N, 5H-pyrrolo (2,3-) benzimidazole-6-OHj
    7-methyl-2- (2-methoxy-4 methylsulfonylmethyl-phenyl) -6,7-dihydro-3N, 5H-pnrrolo (2,3-) benzimidaeol-6-OH;
    7-methyl-2- (2-methoxy-4-aminosulfonyl-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-) 6-benzimidazole-6-OH;
    7-methyl-2- (2-methoxy-4-methylaminosulfonyl-phenyl) -6,7-dihydro-3N, 5H pyrrolo (2,3-) benzimidazole-6-OH;
    7-ethyl-2-phenyl-6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-E.TIL-2-G4- (1H-imidazol-1-yl) -phenylZ-6,7-dihydro-3N, 5H, pyrrolo
    (2,3-f) benzimidazole-6-OH;
    7-methyl-2 (2-methoxy-4-methylsulfonylaminophenyl) -6,7-dihydro-3H, 5H-pyrrolo C2,3-f) benzimidazole-6-OH;
    7-ethyl-2- (2-methoxy-4-N-methyl-
    methylsulfonylamino-phenyl) -6,7-di-hydro-3N, 5H-pyrrolo (2,3-) benzi-tdazole-6-DH;
    7-ethyl-2- (2-methoxy-4-methylsulfonmethyl-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-etyl-2- (2-methoxy-4-ethylsulfo-niloxy-phenyl) -6,7-dihydro-3N, 5H-pyrrolo2,3-f) benzimidazole-6-OH;
    7-ethyl-2 (2-methoxy-4-trifluoromethylsulfonyloxy-phenyl) -6,7-dihydro 3N, 3N-pyrrolo (2,3-f) benzimidazol-6-OH;
    7-ethyl-2- (2-methoxy-4-nitro-pheny 6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimndazol-6-OH;
    7-ethyl-2- (3,4-dimethoxy-phenyl-vinyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-ethyl-2- (2-methoxy 4-hydroxyphenyl) -6.7 dihydro-3H, 5H-pyrrolo (2,3-f) benzisddasol-6-OH;
    7-ethyl-2- (3,4-dichloro-phenyl) -6,7-dihydro-3N, 5H, pyrrolo (2,3-f) benzimy dazol-6-OH;
    7-ethyl-2- (2-methoxy-4-methylamino-carbonylamino-phenyl) -6,7-dihydro; 3H, 5H-pyro (2,3-f), b. G dazol-. 6-OH;
    7--5ti, p-2- (2-methoxy-4-methylsulphonyloxy-fsil) -6,7-dihydro-3N, 5H-tshrolo (2,3-1) benzimidazole-6-OH;
    7-isopropyl-2-phenyl-6,7-dihydro-ZN, 5I-pyrrho; (lo, (2, 3-f) benzimidazol-6-OH;
    7-isopropyl-2- 4- (1H-imidazol-1-yl) -phenyl 1-6,7-dihydro-3N, 5H-pyr (2,3-f) benzimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-methylsulfonyloxy-phenyl) -6,7-dihydro 3N, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-metsh1-aminocarbonylaminophenyl) -6,7-dihydr 3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-methylsulfonylamino-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropyl-1- (2-methoxy-4-nitrophenyl) -6,7-dihydro-3H, 5H-pyrrolo. (2,3-f) ben zimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-nitrophenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-aminophenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropyl-2- (2-methoxy-4-hydroxy-fensh1) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-isopropylidene-2 (2-methoxy-4-hydroxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-acetyl-2- (4-methoxy-phenyl) -6.7 dihydro-3N, 5H-pyropolo (2,3-f) benzimy dazol-6-OH;
    7-acetyl-2- (2-methoxy-4-methylsulononoxy-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-acetyl-2- (2-methoxy-4-methylsulonyl amino-phenyl) -6,7-dihydro-3N, 5H pyrrolo (2,3-f) benzimidazole-6-OH,
    7-acetyl-7-methyl-2- (4-methoxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-acetyl-6-methyl-2- (2-methoxy-4-hydroxyphenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    8-acetyl-6-methyl-2- (2-methoxy-4-methylsulfonylamino-phenyl) -6,7-dihydro-3H, 3H-pyrrolo (2,3-f) benzim
    Dazol-6-OH;
    7-acetal-7-methyl-2-32-methoxy-4-methylsulfonyloxy-fensch-1) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimide-ZOL-6-OH;
    7-methoxycarbonyl-2- (4-methoxy-phenyl) -6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimidazole-6-OH
    ((-methoxycarbonsh-1- 2- (2-methoxy-4-methylsulfonyloxy-phenyl) -6,7-dihydro-3N, 5H-pyrrole o (2, 3-f) benzimidazol-6-OH;
    7-methoxycarbonyl-2- (2-methoxy-4-methylsulfonylaminophenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazol-6-Ofi;
    7-ethoxycarbonyl-7-etsh1-2- (4-methoxy-phenyl -) - 6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-ethoxycarbonyl-7-ethyl-2- (2-methoxy-4-methylsulfonoxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-ethoxycarbonyl-7-ethyl-2- (2-methoxy-4-methylsulfonamine-phenyl) -6,7-dihydro-3N, 5I-pyrrolo (2,3-f) benzimidazol-6-OH,
    7-ethoxycarbonyl-7-methyl-2- - (1H imidazol-1-yl) phenylJ-6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-ethoxycarbonyl-7-methyl-2- (2-methoxy-4-hydroxyphenyl) -6,7-dihydro 3N, 5H-pyrrolo (2, 3-f) benzimidazol-6-OH;
    7-ethoxycarbonyl-7-methyl-2- (240
    methoxy-4-methylsulfonylamino-phenyl) - 5 times from 0, .01 to 30 mg dose. Za-6,7-dihydro-3H, 5H-Pirrolo (2,3-f) benzimidazol-6-OH;
    7-ethoxycarbonyl-7-methyl-2- (2-methoxy-4-methylsulfonyloxy-phenyl) -6,7-dihydro-3H, 5H-PIRRO 6 (2,3-f) benzimidazol-6-OH;
    7-aminocarbonyl-7-methyl-2- (4 methoxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-aminocarbonyl-7-methyl-2- (2-methoxy-4-methylsulfonyloxy-phenyl) -6,7-dihydro-3H, 5H-pyrrolo (2,3-f) benzimidazole-6-OH;
    7-aminocarbonyl-7-methyl-2- (methoxy-4-methylsulfonylaminophenyl) -6.7-50 dihydro-3H, 3H-pyrrolo (2,3-f) benzimidazol-6-OH;
    7-cyano-7-methyl-2- (4-methoxyphenyl, 6,7-dihydro-3N, 5H-pyrrolo (2,3-f) benzimidazol-6-OH; 55
    Dose-effect curves are thus obtained with respect to the registered parameters for the substances under study.
    From the measured data by means of the regression calculation method, equipotential doses are calculated for a positive foreign effect (dp / dt). In addition, as a criterion for the strength of the substances, the achievable maximum of the action (rel. Dp / dt) and the dose related to it are determined. Tab. 5 s will result in a comparison of equipotential doses (DE — such dose in mg / kg, which leads to an increase in the compressive force of the heart of 1.5 MHg / c and the maximum influence force, W,. —The maximum increase in the compressive force dp / dt — baseline values). Brackets indicate attributed to this injected doses of substances.
    7-cnan-7-methyl-2- (2-methoxy-4-methylsulfonyloxy-phenyl) -6,7-dihydro-3H, 5H-pyrrole o (2, 3-f) benzimidazole-6-OH.
    Research methods. Male Sparague-Dawley rats weighing approximately 350-450 g narcotics for research are as follows.
    A catheter is inserted through the Arteria carotis dentra into the left ventricle of the heart to measure pressure (Millar Micropoint) with a diameter of 0.5 mm. Through this measuring sensor continuously record the pressure of the left ventricle of the heart.
    For the purpose of intravenous injection of the test substances, a polypropylene catheter is inserted into the Venagugularic.
    In order to directly measure the arterial blood pressure, another polypropylene catheter is inserted into the abdominal aorta through Arteria femoralis. After subcutaneous electrodes, injected by prick electrodes, the ECG is retracted.
    During the preparation of the animal and during the entire duration of the test, the rats are fixed on an electrically heated and thermostatically controlled operating table.
    The use of the test substances is carried out by intravenous injection and is per injection, 1 mg / kg body weight. In the intervals of 10 minutes intravenous injection t increased
    from 0, .01 to 30 mg dose. Behind-
    Dose-effect curves are thus obtained with respect to the registered parameters for the substances under study.
    From the measured data by means of the regression calculation method, equipotential doses are calculated for a positive foreign effect (dp / dt). In addition, the maximum effect achieved (rel. Dp / dt) and the dose related to it are determined as criteria for the strength of the substances. Tab. 5 s will result in a comparison of equipotential doses (DE — such dose in mg / kg, which leads to an increase in the compressive force of the heart of 1.5 MHg / c and the maximum influence force, W,. —The maximum increase in the compressive force dp / dt — baseline values). Brackets indicate attributed to this injected doses of substances.
    "20
    From the data we can see that the substances of examples 3 and 6 are stronger than the known substances Ref 1 and Ref 2.
    Ref 1 - 3-amino-6-methyl-5-fennl-2 (1H) -pyrridinone-methane sulfonate, 25
    Ref 2 - 3,4-dihydro-6-4- (3,4-dimethoxybenzosh1-1-piperazinyl-2 (1H) -quinoline).
    Ref 3 - 7,7-dimethyl-2-3- (2-methoxy-6-methyl-pyridyl) -6,7-dihydro-3N, 5H-zo pyrrolo (2,3-f) benzimidazole-6- HE.
    权利要求:
    Claims (1)
    [1]
    The compounds obtained are of low toxicity. Invention Formula
    The method of obtaining pyrrole-benzimide-35 azoles of the general formula
    4 03 -i8 R
    20
    ten
    15
    20
    25
    n K; - may be the same or different and denote each hydrogen atom, alkoxy group, lower alkyl, halogen atom, alkylsulfonyloxy, amino-acetyl-amino group, 1H-imidazole, alkylsulfonylamino, cyano, carbonyl aminocarbonyl, alkoxycarbonyl , alkylmercapto, dialkylamino, trifluoromethyl, alkylsulfinyl or alkylsulfonal, X is a valence bond, the lower
    alkylene or vinylene, or their physiologically compatible salts of inorganic acids, of which it is
    Ri
    N
    n
    about
    where R, R have the indicated meanings are reacted with a compound of the general formula
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1440348A3|1988-11-23|Method of producing pyrrole-benzymidazoles or physiologically compatible salts ofinorganic acids thereof
    US4666908A|1987-05-19|5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
    US5512677A|1996-04-30|3-substituted methyl-2,3-dihydroimidazo 1,2-c!quinazoline derivatives, the preparation and use thereof
    SU1470191A3|1989-03-30|Method of producing pyrrolobenzimidazols or their tautomers, or their physiologically compatible salts of inorganic acids
    US4863945A|1989-09-05|Pyrrolobenzimidazoles and pharmaceutical compositions containing them
    DD272649A5|1989-10-18|NEW TRICYCLIC BENZIMIDAZOLE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT
    DE2854115A1|1979-07-12|NEW CONDENSED PYRIMIDINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
    RU2497812C2|2013-11-10|Imidazolidine-2,4-dione drivatives and using them as anti-cancer drug
    US4840948A|1989-06-20|1-|-5H-2,3-benzodiazepine derivatives, and pharmaceutical compositions containing the same
    NZ201659A|1984-07-31|Benz-amino-1,2,4,5-tetrahydroimidazo|-quinazolin-2-ones
    DE3504677A1|1986-08-14|Novel imidazol-2-yloxyalkanoic acids and their derivatives, processes for their preparation and pharmaceutical preparations containing them
    SU1574177A3|1990-06-23|Method of obtaining derivatives of 4,5-dihydrooxazoles 4,5-substituted andro stendioneor their pharmaceutically acceptable salts
    US5340814A|1994-08-23|3-substituted methyl-2,3-dihydroimidazo[1,2-C] quinazoline derivatives, the preparation and use thereof
    SU1409129A3|1988-07-07|Method of producing quinazolinedions
    EP1252163B1|2003-09-24|4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
    US4190659A|1980-02-26|Pharmaceutical preparation and use of 4-hydroxy-2-quinolinone-3-carboxylic acid esters
    CA2049490A1|1992-03-01|Pyrrolobenzimidazoles, imidazobenzoxazinones and imidazoquinolones, process for their preparation and their use and preparations containing the compounds
    EP0252422B1|1991-07-24|Pyridazinone derivatives and salts thereof
    SU978731A3|1982-11-30|Method of producing derivatives of pyrasole/1,5-c/ quinazolenes or their salts
    DE2233682A1|1973-10-11|2- SQUARE CLAMP ON 3- | -4-H-1,2,4-TRIAZOL-4-YL SQUARE CLIP ON -BENZOPHENONE, A PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINED
    US5114944A|1992-05-19|2-phenylpyrazolo[1,5-a]pyrimidine-3-acetic acid derivatives exhibiting therapeutic effects
    RU1830064C|1993-07-23|Method for producing hydrazides of 4-chlor-3-sulfamoylbenzoic acid of their pharmaceutically available salts
    EP0047412B1|1984-07-25|Pyrazines, their preparation and pharmaceutical compositions containing them
    RU2161160C2|2000-12-27|Method of preparing 6,8-dimethyl-2-piepridino methyl-2,3-dihydrothiazolo [2,3-f] xanthine
    SU1205768A3|1986-01-15|Method of producing 2-guanidine-4-thiazolthiazole derivatives or their acid-additive pharmaceutically acceptable salts
    同族专利:
    公开号 | 公开日
    ES549776A0|1987-01-16|
    EP0186010A1|1986-07-02|
    DK579185A|1986-06-15|
    AU5100685A|1986-06-19|
    ES8702409A1|1987-01-16|
    CA1262908A|1989-11-14|
    CS276403B6|1992-05-13|
    DD242045A5|1987-01-14|
    EP0186010B1|1990-01-31|
    ZA859382B|1986-08-27|
    CS919585A3|1992-01-15|
    FI854926A0|1985-12-12|
    DE3445669A1|1986-06-19|
    JPH0471914B2|1992-11-16|
    US4810801A|1989-03-07|
    HUT40436A|1986-12-28|
    HU194241B|1988-01-28|
    AT49970T|1990-02-15|
    DK579185D0|1985-12-13|
    FI79318C|1989-12-11|
    GR852979B|1986-04-08|
    FI854926A|1986-06-15|
    US4710510A|1987-12-01|
    FI79318B|1989-08-31|
    JPS61158984A|1986-07-18|
    AU580822B2|1989-02-02|
    DE3575725D1|1990-03-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4234571A|1979-06-11|1980-11-18|Syntex Inc.|Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone|
    EP0033612B1|1980-02-02|1984-04-11|Beecham Group Plc|Pyrano derivatives, a process for their preparation and antihypertensive compositions containing them|
    FR2476644B1|1980-02-21|1984-02-17|Sarget Lab|
    DE3224512A1|1982-07-01|1984-01-05|Dr. Karl Thomae Gmbh, 7950 Biberach|NEW IMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    SU1068439A1|1982-10-28|1984-01-23|Новокузнецкий научно-исследовательский химико-фармацевтический институт|Derivatives of imidazo indoles|
    US4579865A|1983-02-14|1986-04-01|Usv Pharmaceutical Corp.|Benzofuranyl carbamates|
    US4548943A|1984-05-11|1985-10-22|E. I. Du Pont De Nemours And Company|Antiinflammatory, analgesic, or anti-primary dysmenorrheal arylmethylene- and arylmethylindenoimidazoles|
    PL147842B1|1984-05-12|1989-08-31|Method of obtaining novel pyroisobenzimidazoles|
    DE3501497A1|1985-01-18|1986-07-24|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS|
    DE3531678A1|1985-09-05|1987-03-12|Boehringer Mannheim Gmbh|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|DE3501497A1|1985-01-18|1986-07-24|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS|
    DE3531678A1|1985-09-05|1987-03-12|Boehringer Mannheim Gmbh|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    DE3626664A1|1986-08-07|1988-02-11|Boehringer Mannheim Gmbh|TRICYCLIC BENZOTRIAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|
    DE3639466A1|1986-11-18|1988-05-19|Thomae Gmbh Dr K|NEW PYRROLO-BENZIMIDAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF|
    DE3642315A1|1986-12-11|1988-06-23|Boehringer Mannheim Gmbh|NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|
    DE3701277A1|1987-01-17|1988-07-28|Boehringer Mannheim Gmbh|NEW TRICYCLIC BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS|
    DE3740985A1|1987-12-03|1989-06-15|Boehringer Mannheim Gmbh|USE OF LINEAR FURNISHED TRICYCLES AS AN INHIBITORS OF THE ERYTHROCYTE AGGREGATION|
    US4963677A|1987-12-30|1990-10-16|Orion Corporation Ltd.|Heterocyclic lactam compounds|
    AT138658T|1987-12-30|1996-06-15|Orion Yhtymae Oy|HETEROCYCLIC COMPOUNDS|
    DE3803775A1|1988-02-09|1989-08-17|Boehringer Mannheim Gmbh|NEW SUBSTITUTED LACTAME, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    DE4027592A1|1990-08-31|1992-03-05|Beiersdorf Ag|NEW PYRROLOBENZIMIDAZOLE, IMIDAZOBENZOXAZINONE AND IMIDAZOCHINOLONE, PROCESS FOR THEIR PREPARATION AND THEIR USE AND THE COMPOUNDS CONTAINING PREPARATIONS|
    US7186745B2|2001-03-06|2007-03-06|Astrazeneca Ab|Indolone derivatives having vascular damaging activity|
    WO2002072549A1|2001-03-12|2002-09-19|Millennium Pharmaceuticals, Inc.|Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor|
    JP2007518816A|2004-01-23|2007-07-12|アムジエン・インコーポレーテツド|Vanilloid receptor ligands and their use in the treatment of inflammatory and neuropathic pain|
    SG11201501923WA|2012-09-13|2015-04-29|Hoffmann La Roche|2-oxo-2,3-dihydro-indoles for the treatment of cns disorders|
    BR112017002053A2|2014-08-01|2018-01-30|Nuevolution A/S|compound according to formula , pharmaceutical composition, and uses of a compound|
    GB201709456D0|2017-06-14|2017-07-26|Ucb Biopharma Sprl|Therapeutic agents|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19843445669|DE3445669A1|1984-12-14|1984-12-14|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    [返回顶部]